GlassScriptPhysician profile
Elisha I Lancaster
NPI 1316136567
$2,142.36
in general payments reported to CMS, 2019-2025
25 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $61.87 · 2021: $82.03 · 2022: $197 · 2023: $378 · 2024: $477 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $254.95 | 2022-2025 | |
| Amgen INC. | $241.88 | 2019-2025 | Krystexxa, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.35 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $188.24 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $177.19 | 2019-2023 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals LP | $173.98 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $123.88 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $123.53 | 2023-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $104.88 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $74.35 | 2021-2023 | Krystexxa |
| Bard Peripheral Vascular, INC. | $73.89 | 2019-2024 | Covera, Atlas |
| Ani Pharmaceuticals, INC. | $56.95 | 2022-2023 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $41.74 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $38.49 | 2025 | Lupkynis |
| Novo Nordisk INC | $36.41 | 2023 | Rybelsus, Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $35.57 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $33.11 | 2019-2024 | Ultomiris |
| Scpharmaceuticals INC. | $23.17 | 2024 | |
| Ardelyx, INC. | $21.39 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $17.85 | 2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $15.89 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.55 | 2025 | Empaveli |
| Recor Medical INC | $15.29 | 2024 | Paradise Renal Denervation System |
| Shire North American Group INC | $11.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisha Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.